Irish biotech startup targeting inflammatory diseases acquired by Roche

Headquartered in Dublin, the company is developing drugs to address clinical unmet needs in inflammatory diseases

Dr Manus Rogan, Chairman & Co-founding investor, Dr Matt Cooper, Co-founder & Chief Executive Officer, Prof. Luke O'Neill, Co-founder & Chief Scientific Officer and Dr Jeremy Skillington, Vice President, Business Development. Picture: Nick Bradshaw

A startup company developing treatments for inflammatory diseases based on a research partnership between the University of Queensland (UQ) and Trinity College Dublin has been acquired in a landmark deal, one of the largest in Australian and Irish biotech history.

Inflazome has been acquired by Roche for an upfront cash payment of €380 million, plus additional payments based on the achievement of certain milestones.